<DOC>
	<DOCNO>NCT01636102</DOCNO>
	<brief_summary>To evaluate safety single intramuscular ( IM ) injection trivalent nonadjuvated influenza study vaccine , formulation 2012/2013 , adult elderly subject antibody response influenza vaccine antigen , measure single radial hemolysis ( SRH ) hemagglutination inhibition ( HI ) approximately 21 day postimmunization adult elderly subject compliance requirement current EU recommendation clinical trial relate yearly license influenza vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Subunit Trivalent Nonadjuvated Influenza Study Vaccine Adults Aged 18 Years Above</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Male female volunteer 18 year age old ; 2 . Individuals able comply study requirement ; 3 . Individuals good health determine outcome medical history , physical examination clinical judgment investigator 1 . Individuals behavioral cognitive impairment psychiatric disease , opinion investigator , could interfere subject 's ability participate study . 2 . Individuals serious chronic acute disease ( judgment investigator ) , include limited : Medically significant cancer ( except benign localize skin cancer , cancer remission ≥10 year localized prostate cancer clinically stable 2 year without treatment ) ; Medically significant advance congestive heart failure ( ie . NYHA class III IV ) ; Chronic obstructive pulmonary disease ( COPD ; i.e. , GOLD Stage III IV ) ; Autoimmune disease ( include rheumatoid arthritis , except Hashimoto 's thyroiditis clinically stable ≥5 year ) ; Diabetes mellitus type I ; Poorly control diabetes mellitus type II ; Advanced arteriosclerotic disease ; History underlie medical condition major congenital abnormality require surgery , chronic treatment , associate developmental delay ( e.g. , Down 's syndrome ) ; Acute progressive hepatic disease ; Acute progressive renal disease ; Severe neurological ( es . GuillainBarré syndrome ) psychiatric disorder ; Severe asthma . 3 . Individuals history anaphylactic reaction and/or serious allergic reaction follow vaccination , proven hypersensitivity component study vaccine ( e.g . egg eggs product well ovalbumin , chicken protein , chicken feather , influenza viral protein , kanamycin neomycin sulphate ) . 4 . Individuals know suspect ( high risk develop ) impairment/alteration immune function ( exclude normally associate advanced age ) resulting , example , : receipt immunosuppressive therapy ( parenteral oral corticosteroid cancer chemotherapy/radiotherapy ) within past 60 day full length study ; receipt immunostimulants ; receipt parenteral immunoglobulin preparation , blood product and/or plasma derivates within past 3 month full length study ; suspect know HIV infection HIVrelated disease . 5 . Individuals know suspected history drug alcohol abuse . 6 . Individuals bleed diathesis condition associate prolonged bleeding time investigator 's opinion could interfere safety subject . 7 . Individuals able comprehend follow require study procedure whole period study . 8 . Individuals history illness , opinion investigator , pose additional risk subject due participation study . 9 . Individuals within past 6 month : laboratory confirm seasonal pandemic influenza disease ; receive seasonal pandemic influenza vaccine . 10 . Individuals receive vaccine within 4 week prior enrollment study planning receive vaccine study . 11 . Individuals acute chronic infection require systemic antibiotic treatment antiviral therapy within last 7 day . 12 . Individuals experience fever ( i.e. , axillary temperature ≥38°C ) within last 3 day intend study vaccination . 13 . Individuals participate clinical trial another investigational product 4 week prior first study visit intent participate another clinical study time conduct study . 14 . Individuals part study personnel close family member conduct study . 15 . BMI &gt; 35 kg/m2 . 16 . Females pregnant ( confirm positive urine pregnancy test ) nursing ( breastfeed ) . Females childbearing potential refuse use acceptable method birth control whole duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Adults</keyword>
	<keyword>Elderly</keyword>
	<keyword>Immunology</keyword>
	<keyword>Safety</keyword>
</DOC>